There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT05130801
Recruiting
The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. During the Phase I... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey +1 locations
Conditions: Breast Cancer
Register for Updates
UNC Pleural Fluid Registry
NCT05620329
Recruiting
Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid regi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: UNC Lingeberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
Register for Updates
Perioperative Mindfulness Proposal
NCT04049214
Recruiting
The purpose of this study is to determine if a regular meditation and breath work practice started before surgery and continued through post-surgical recovery can improve anxiety and pain related to breast cancer and its treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Breast Cancer, DCIS
Register for Updates
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Providence St. Johns Health Center, Santa Monica, California +6 locations
Conditions: Breast Cancer
Register for Updates
Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling
NCT04965064
Recruiting
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Rochester, Rochester, New York
Conditions: Breast Cancer
Register for Updates
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
NCT06008275
Recruiting
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Register for Updates
Precise Oncology Interventions in Nutrition and Training (OnPoint)
NCT06534918
Recruiting
The purpose of this study is to see if survivors of breast, prostate, or colorectal cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Register for Updates
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT06582849
Recruiting
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing \>10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants to historic controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Register for Updates
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer
NCT06361940
Recruiting
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Breast Cancer
Register for Updates
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
NCT05508906
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +15 locations
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Stamford Hospital, Stamford, Connecticut +27 locations
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT04454528
Recruiting
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer. The secondary objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and histology exams, and to assess immune response on pre and post treatment blood and tissue samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes. A clinically sign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates